Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Assessment of the therapeutic potential of anti-miR 24 and anti-miR 34 in cardiac diseases

Chunli Li, Jue Li, Xiaojun Sun , Jin Huang, Chunyan Yao

Department of Cardiovascular Medicine, Wenshan People's Hospital, 228 Kaihua Middle Road, Wenshan City, Yunnan Province 663000, China;

For correspondence:- Xiaojun Sun Email: JoyTrevinoqcu@yahoo.com Tel:+868762127918

Accepted: 25 June 2020 Published: 31 July 2020

Citation: Li C, Li J, Sun X, Huang J, Yao C. Assessment of the therapeutic potential of anti-miR 24 and anti-miR 34 in cardiac diseases. Trop J Pharm Res 2020; 19(7):1435-1440 doi: 10.4314/tjpr.v19i7.15

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the therapeutic effects of anti-miR-24 and anti-miR-34 in cardiac diseases

Methods: H9c2 rat cardiomyocyte cell lines were transfected with the synthetic oligonucleotides anti-miR-24 and anti-miR-34 which reduced the expressions of miR-24 and miR-34. Proliferation assay, real time-polymerase chain reaction (RT-PCR) and immunoblotting were carried out to determine the effect of the transfections on cardiomyocyte proliferation, expressions of miR-24 and miR-34, as well as expressions of the target genes, TGF-β1 and E2F3.

Results: The proliferation ability of the transfected cells was decreased significantly, relative to negative control. In contrast, percentage apoptosis was higher in the negative control group than in transfected cells. The expression profiles of anti-miR-24 and anti-miR-34 were significantly reduced, when compared to negative control. These results were further confirmed using immunoblot which revealed that the expression of the target genes, TGF-β1 and E2F3, were upregulated in the transfected cells.

Conclusion: These results suggest that the synthetic oligonucleotides (anti-miR-24 and anti-miR-34) might be useful in developing therapeutic drug targets for cardiac diseases by suppressing the expressions of miR-24 and miR-34.

Keywords: H9c2rat cardiomyocyte miRNA, Anti-miR-24, Anti-miR-34, Cardiac diseases